Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment ...

If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years MARBURG, ...

CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping out’. The world-class facility will ...

For additional photos, logos and other branding elements, visit Brand.csl.com and Create an Account in the External Users Only box.